Format

Send to

Choose Destination
Nat Med. 2012 Dec;18(12):1835-40. doi: 10.1038/nm.2994. Epub 2012 Nov 11.

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy.

Author information

1
Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Abstract

Glioblastomas shed large quantities of small, membrane-bound microvesicles into the circulation. Although these hold promise as potential biomarkers of therapeutic response, their identification and quantification remain challenging. Here, we describe a highly sensitive and rapid analytical technique for profiling circulating microvesicles directly from blood samples of patients with glioblastoma. Microvesicles, introduced onto a dedicated microfluidic chip, are labeled with target-specific magnetic nanoparticles and detected by a miniaturized nuclear magnetic resonance system. Compared with current methods, this integrated system has a much higher detection sensitivity and can differentiate glioblastoma multiforme (GBM) microvesicles from nontumor host cell-derived microvesicles. We also show that circulating GBM microvesicles can be used to analyze primary tumor mutations and as a predictive metric of treatment-induced changes. This platform could provide both an early indicator of drug efficacy and a potential molecular stratifier for human clinical trials.

PMID:
23142818
PMCID:
PMC3518564
DOI:
10.1038/nm.2994
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center